Everest Organics Peer Comparison

BSE: 524790

₹251.05

₹0.55 (0.22%)

As on 18-Sep-2026IST

Market cap

₹250 Cr

Revenue (TTM)

₹191 Cr

P/E Ratio

47.6

P/B Ratio

3.1

Div. Yield

0 %

Edit

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	250	20,887	19,967	18,310	18,305
Revenue (₹ Cr)	191	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	5.26	678.07	273.51	666.92	735.15
Net Margin (%)	2.74	28.10	16.19	20.60	26.88
RoE (%)	7.10	19.73	11.15	18.75	19.16
Price to Earnings	47.65	31.39	67.16	28.44	24.90
Price-To-Book	3.11	5.69	7.43	4.54	4.15

Income Statement (₹ Cr)

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	190.78	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	191.89	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	171.07	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	19.70	796.58	478.55	1,139.61	941.63
Depreciation	6.56	78.10	126.01	281.06	57.58
EBIT	13.15	718.48	352.55	858.55	884.05
Interest	6.85	0.88	52.11	190.64	7.69
Other Income	1.12	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	7.41	843.56	319.96	658.12	992.82
Provision for Tax	2.16	165.49	46.45	-8.80	257.67
Profit after Tax	5.26	678.07	273.51	666.92	735.15

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	75.48	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	0.00	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	12.13	28.74	266.35	1,392.75	91.50
Current Liabilities	152.20	385.94	848.06	2,077.10	627.48
Total Liabilities	224.48	3,207.85	3,310.68	6,865.52	4,911.11

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	68.38	1,291.22	2,525.44	5,617.77	770.28
Current Assets	167.43	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	224.48	3,207.85	3,310.68	6,865.52	4,911.11
Total Debt*	47.87	0.55	586.37	2,421.66	2.50
Net Current Assets	15.23	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	5.54	0.64	76.22	51.96	363.79

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	-5.38	432.37	132.27	1,065.01	659.75
Cash Flow from Investing Activities	-5.17	-334.73	-199.13	-79.97	-71.34
Cash from Financing Activities	16.36	-38.32	62.65	-881.32	-205.34
Net Cash Inflow / Outflow	5.82	59.32	-4.21	103.72	383.07

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	1.76	26.22	6.95	13.59	26.21
ROE (%)	7.10	19.73	11.15	18.75	19.16
ROA (%)	2.26	18.69	7.80	9.26	14.95
EBIT Margin (%)	6.89	31.41	20.95	26.58	34.40
Net Margin (%)	2.74	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	5.49	15.01	27.91	9.59	10.69
EBIT Growth (%)	41.22	18.45	58.32	16.84	24.14
Net Profit Growth (%)	-15.23	19.61	149.56	62.68	-9.09
EPS Growth (%)	-20.40	17.73	-3.57	67.41	14.40
Book Value Growth (%)	50.41	23.77	30.63	10.19	17.30

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	46.39	31.39	71.24	27.75	23.73
Price / Book Value	3.11	5.69	7.43	4.54	4.15
Dividend Yield (%)	0.00	0.29	0.06	0.00	1.87
EV/EBITDA	14.80	24.96	43.00	18.03	16.14
Market Cap (₹ Cr)	244.70	15,219.80	6,484.12	19,292.77	18,318.10

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.10	0.00	0.07	0.24	0.00
Short term debt to equity ratio	0.48	0.00	0.13	0.14	0.00
Current Ratio	1.10	6.70	1.31	0.74	6.06
Quick Ratio	0.81	5.59	0.88	0.53	5.31
Interest Coverage	2.08	959.59	7.14	4.45	130.11

	Everest Organics	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	60.89	36.10	30.84	21.07	7.07
Asset Turnover	0.82	0.63	0.48	0.45	0.52
Receivable days	188.66	110.70	118.15	54.06	29.10
Inventory Days	89.08	65.86	98.29	32.16	69.53
Payable days	382.32	105.88	128.16	140.91	76.77
Cash Conversion Cycle	-104.59	70.68	88.28	-54.69	21.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.